120 results
Page 3 of 6
6-K
EX-99.1
xioq6 55f88
6 Jan 22
ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain
6:30am
6-K
EX-99.1
vr37xh 09
17 Dec 21
ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
7:15am
6-K
EX-99.1
eel26tajmud7qyny 5h
13 Dec 21
ObsEva Appoints Will Brown as Chief Financial Officer
7:00am
6-K
EX-99.1
g0rlinan9ljr59g
10 Dec 21
ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021
8:12am
6-K
EX-99.1
yj7u68dgbogzsn
22 Nov 21
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
6:05am
6-K
EX-99.2
p937toymelrpc
22 Nov 21
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
6:05am
6-K
EX-99.3
2b7q0v9x
4 Nov 21
Index to Unaudited Condensed Consolidated Financial Statements
7:21am
6-K
EX-99.1
9gm4n
29 Oct 21
ObsEva Announces Management Change
5:24pm
6-K/A
EX-99.1
v2thsw2oodrsb6na
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
6-K/A
EX-99.2
zrc7c
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
6-K/A
EX-99.5
9lunn 17aciut
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
6-K
r6n36lty b7gwbj7
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
6-K
EX-99.2
rt5j1d2lq7os b2y
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
6-K
EX-99.1
8z6y74y
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
6-K
EX-99.5
e0qi3nlw lrr9i
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
6-K
EX-99.1
8vbj187yoa0ui uuj
27 Jul 21
Current report (foreign)
6:12am
6-K
EX-99.1
b6cklb0jhd1umuxq3l
20 May 21
ObsEva Announces Final Results from the Phase 3 PRIMROSE Program of
6:30am
6-K
EX-99.1
sgtp6zb2cgpkohw z6x5
6 May 21
ObsEva appoints Clive Bertram as Chief Commercial Officer
6:05am
6-K
EX-99.3
jzonxb45289nktvtgb
6 May 21
Index to Unaudited Condensed Consolidated Financial Statements
6:03am
6-K
EX-1.1
virklfqohn5v
5 Mar 21
Current report (foreign)
8:15am